NEW YORK, May 25, 2017 /PRNewswire/ --
The Biotech space consists of companies engaged in the research and development
Shares in Seattle, Washington headquartered Juno Therapeutics Inc. rose 2.14%, ending Wednesday's trading session at $25.33. The stock recorded a trading volume of 906,507 shares. The Company's shares have gained 1.52% in the last one month, 14.51% over the last three months, and 34.38% on an YTD basis. The stock is trading 7.46% and 2.27% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have a Relative Strength Index (RSI) of 56.27.
On May 05th, 2017, research firm FBR & Co. reiterated its 'Market Perform' rating on the Company's stock with a decrease of the target price from $30 a share to $29 a share.
On May 23rd, 2017, Juno Therapeutics announced that it has appointed Jay Flatley to its Board of Directors. Mr. Flatley served as Executive Chairman of Illumina, Inc. from 1999 to 2016, and during his tenure grew the company's annual revenue from just over $1 million to more than $2 billion. He also oversaw the growth of the company from 20 employees to over 5,000. Visit us today and download your complete report on JUNO for free at:
San Francisco, California headquartered Nektar Therapeutics' stock jumped 6.84%, closing the day at $21.10. A total volume of 2.88 million shares was traded, which was above their three months average volume of 2.19 million shares. The Company's shares have advanced 8.82% in the past month, 59.85% in the previous three months, and 71.96% since the start of this year. The stock is trading 7.20% and 32.65% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Nektar Therapeutics, which develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the US, have an RSI of 60.10.
On May 18th, 2017, Nektar Therapeutics announced its presence at the 2017 American Society of Clinical Oncology Annual Meeting, which will take place from June 02nd, 2017 to June 06th, 2017 in Chicago. The Company will share updated data from clinical studies of NKTR-214, an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting CD8+ effector T cells and natural killer cells directly in the tumor microenvironment. The complimentary research report on NKTR can be accessed at:
On Wednesday, shares in South San Francisco, California headquartered Threshold Pharmaceuticals Inc. recorded a trading volume of 133,502 shares. The stock ended the day 0.25% lower at $0.47. The Company's shares have advanced 6.53% since the start of this year, and are trading below their 50-day moving average by 11.45%. Furthermore, shares of Threshold Pharma, which discovers and develops therapeutic and diagnostic agents that target tumor cells for the treatment of cancer patients in the US, have an RSI of 40.71.
On May 15th, 2017, Threshold Pharma reported financial results for Q1 ended March 31st, 2017. R&D expenses for the quarter were $1.6 million; general and administrative expenses were $2.9 million; non-cash stock-based compensation expense, included in total operating expenses, was $0.5 million; and net loss was $5.1 million. Additionally, cash, cash equivalents, and marketable securities totaled $17.6 million at March 31st, 2017. Register for free on Stock-Callers.com and download the PDF research report on THLD at:
Warren, New Jersey headquartered Bellerophon Therapeutics Inc.'s stock dropped 2.80%, finishing yesterday's session at $1.39 with a total trading volume of 259,946 shares. The Company's shares have advanced 0.72% in the last one month, 15.83% in the previous three months, and 167.20% on an YTD basis. The stock is trading above its 200-day moving average by 19.07%. Additionally, shares of Bellerophon Therapeutics, which focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases, have an RSI of 45.25.
On May 15th, 2017, Bellerophon Therapeutics reported financial results for Q1 ended March 31st, 2017. The Company reduced its loss from operations to $4.8 million during the quarter, and had cash and cash equivalents, restricted cash, and marketable securities of $17.1 million at March 31st, 2017. The Company also reported net loss per share of $0.60 in Q1 2017 compared to $0.54 net loss per share in the prior-year's same period. Get free access to your research report on BLPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...View All